Divergent Analyst Views on Symrise Highlight a Pivotal Year Ahead

JPMorgan (€100 target) and Berenberg (€81.20) diverge on near-term price but agree on a potential H2 2026 recovery for Symrise, contrasting its current oversold market state.

Financial analysts at Berenberg and JPMorgan have issued updated research on Symrise, presenting a nuanced outlook for the flavor and fragrance giant. While their near-term forecasts and price targets differ significantly, a common thread emerges: both institutions are looking toward the latter half of 2026 for a potential operational turnaround, a view currently at odds with the stock's market performance.

Market Performance Contrasts with Analyst Scenarios

The shares of Symrise are currently trading under considerable pressure, presenting a stark contrast to the analysts' medium-term expectations. Over the past twelve months, the stock has declined by approximately 26%. Technical indicators underscore the selling pressure, with a 14-day Relative Strength Index (RSI) reading of 27.5, a level typically signaling an oversold condition. This weakness is not isolated to Symrise; peers in the sector, including Givaudan and Henkel, have also faced recent losses, pointing to broader challenges within the industry.

JPMorgan Maintains a Bullish Stance

In its assessment, JPMorgan expresses notable confidence. Analyst Edward Hockin reaffirmed an "Overweight" rating on the stock yesterday, maintaining a price target of €100. This projection implies a substantial upside potential of nearly 43% from yesterday's closing price of €70.10. Hockin acknowledges the likelihood of a subdued first quarter but anticipates a robust recovery later in the year, aligning his view with the guidance provided by Symrise's management.

Berenberg Adopts a More Cautious Tone

Adopting a more reserved position, Berenberg analyst Fulvio Cazzol also revised his figures yesterday. He increased his price target from €79.25 to €81.20 but kept a "Hold" recommendation in place. This adjustment follows the company's solid financial results released in early March. Cazzol forecasts a marked operational acceleration beginning in the second quarter, after a slow start to the year. However, he concurrently cautioned that current consensus estimates for organic growth may be slightly too optimistic.

The Path Forward Hinges on Execution

The discrepancy between the two banks' targets—€100 versus €81.20—highlights the uncertainty surrounding the timing and strength of the anticipated recovery. The coming quarterly financial reports will be critical in determining whether the growth acceleration predicted by both analyst houses materializes. These results will ultimately test the validity of the current price targets and indicate if any revisions are necessary. For now, the market appears to be discounting the optimistic second-half narrative, waiting for concrete signs of improvement.